Chronic graft-versus-host disease in the training and testing sets
| Variable . | IBMTR-1 n = 727 . | IBMTR-2 n = 421 . | NMDP n = 378 . |
|---|---|---|---|
| Designation | Training | Validation | Validation |
| Median time to onset cGVHD, d (range) | 136 (60-1327) | 140 (60-1266) | 122 (66-1127) |
| Type of onset, n (%) | |||
| Progressive | 157 (22) | 132 (31)‡ | 73 (19)2-153 |
| Interrupted | 314 (43) | 138 (33) | 260 (69) |
| De novo | 256 (35) | 151 (36) | 45 (12) |
| Prior acute GVHD, n (%) | 470 (65) | 270 (64) | 333 (88)2-153 |
| Median platelet count at onset × 109/L (range) | 131 (5-999) | 114 (0-548)‡ | 91 (1-448)2-153 substantial missing data |
| Karnofsky performance status at onset, median (range) | 80 (20-100) | 80 (20-100) | 70 (20-100)2-153 substantial missing data |
| Total bilirubin > 2 mg/dL at onset2-153, n (%) | Not collected | 55 (16) substantial missing data | 21 (22) substantial missing data |
| Chronic GVHD, n (%) | |||
| Limited | 350 (48) | 225 (54) | 58 (15)2-153 |
| Extensive | 377 (52) | 191 (46) | 319 (85) |
| Severity at onset, n (%) | |||
| Mild | 381 (52) | 215 (51) | Not collected |
| Moderate | 247 (34) | 142 (34) | |
| Severe | 99 (14) | 62 (15) | |
| New cGVHD grade, n (%) | |||
| Low risk | 365 (50) | 256 (61)* | 64 (34)† |
| Intermediate risk | 232 (32) | 98 (23) | 79 (42) |
| High risk | 130 (18) | 67 (16) | 45 (24) |
| Not able to classify, n | 190 | ||
| Treatment, % | |||
| Cyclosporine | 60 | 812-153 | 932-153 |
| Tacrolimus | Not collected | 4 | Not collected |
| Topical steroids | 15 | 18 | 17 |
| Systemic steroids | 81 | 84 | 952-153 |
| ATG/ALS | 2 | 6† | 6‡ |
| Azathioprine | 14 | 11 | 14 |
| Thalidomide | 9 | 8 | 12 |
| Resolution of cGVHD2-155, n (%) | 245 (34) | Not collected | Not collected |
| Time to resolution of cGVHD from onset date, d (range)2-155 | 369 (79-1545) | Not collected | Not collected |
| Variable . | IBMTR-1 n = 727 . | IBMTR-2 n = 421 . | NMDP n = 378 . |
|---|---|---|---|
| Designation | Training | Validation | Validation |
| Median time to onset cGVHD, d (range) | 136 (60-1327) | 140 (60-1266) | 122 (66-1127) |
| Type of onset, n (%) | |||
| Progressive | 157 (22) | 132 (31)‡ | 73 (19)2-153 |
| Interrupted | 314 (43) | 138 (33) | 260 (69) |
| De novo | 256 (35) | 151 (36) | 45 (12) |
| Prior acute GVHD, n (%) | 470 (65) | 270 (64) | 333 (88)2-153 |
| Median platelet count at onset × 109/L (range) | 131 (5-999) | 114 (0-548)‡ | 91 (1-448)2-153 substantial missing data |
| Karnofsky performance status at onset, median (range) | 80 (20-100) | 80 (20-100) | 70 (20-100)2-153 substantial missing data |
| Total bilirubin > 2 mg/dL at onset2-153, n (%) | Not collected | 55 (16) substantial missing data | 21 (22) substantial missing data |
| Chronic GVHD, n (%) | |||
| Limited | 350 (48) | 225 (54) | 58 (15)2-153 |
| Extensive | 377 (52) | 191 (46) | 319 (85) |
| Severity at onset, n (%) | |||
| Mild | 381 (52) | 215 (51) | Not collected |
| Moderate | 247 (34) | 142 (34) | |
| Severe | 99 (14) | 62 (15) | |
| New cGVHD grade, n (%) | |||
| Low risk | 365 (50) | 256 (61)* | 64 (34)† |
| Intermediate risk | 232 (32) | 98 (23) | 79 (42) |
| High risk | 130 (18) | 67 (16) | 45 (24) |
| Not able to classify, n | 190 | ||
| Treatment, % | |||
| Cyclosporine | 60 | 812-153 | 932-153 |
| Tacrolimus | Not collected | 4 | Not collected |
| Topical steroids | 15 | 18 | 17 |
| Systemic steroids | 81 | 84 | 952-153 |
| ATG/ALS | 2 | 6† | 6‡ |
| Azathioprine | 14 | 11 | 14 |
| Thalidomide | 9 | 8 | 12 |
| Resolution of cGVHD2-155, n (%) | 245 (34) | Not collected | Not collected |
| Time to resolution of cGVHD from onset date, d (range)2-155 | 369 (79-1545) | Not collected | Not collected |